Tazeen Ahmad
Stock Analyst at B of A Securities
(2.43)
# 2,346
Out of 4,840 analysts
202
Total ratings
45.03%
Success rate
-1.72%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma | Maintains: Underperform | $1 → $0.8 | $0.92 | -13.04% | 3 | May 19, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $28 → $27 | $13.42 | +101.19% | 3 | May 19, 2025 | |
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | $41 → $23 | $17.44 | +31.88% | 7 | May 9, 2025 | |
| PTCT PTC Therapeutics | Upgrades: Buy | $55 → $68 | $45.93 | +48.05% | 17 | May 9, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $63 → $68 | $62.32 | +9.11% | 8 | Apr 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $302 → $325 | $289.96 | +12.08% | 3 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Buy | $54 → $28 | $6.51 | +330.11% | 2 | Mar 12, 2025 | |
| MRUS Merus | Maintains: Buy | $73 → $70 | $55.14 | +26.95% | 5 | Mar 10, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $42 → $40 | $3.49 | +1,046.13% | 4 | Mar 10, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $184 → $179 | $120.18 | +48.94% | 3 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $22 | $6.58 | +234.35% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $11.47 | +91.80% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.46 | +105.48% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $68 → $90 | $64.25 | +40.08% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.22 | +141.16% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $6 | $6.53 | -8.12% | 14 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $191 | $162.00 | +17.90% | 8 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $150 | $98.68 | +52.01% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $6.44 | -68.94% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $587.61 | +3.30% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $213 | $37.90 | +462.01% | 21 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $35.66 | +113.12% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $22 | $21.98 | +0.09% | 13 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $3.96 | +253.54% | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $2.11 | +373.93% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.16 | +417.24% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $7.31 | +105.34% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $15.99 | -31.21% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $10.59 | -5.57% | 11 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $2.43 | -17.70% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $0.88 | +581.90% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $8.07 | +85.87% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $37.49 | +60.04% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.23 | +1,200.81% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $9.49 | +353.11% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $168.77 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $8.53 | +3,419.06% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $0.70 | +1,191.25% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $25.82 | +85.90% | 6 | Oct 10, 2018 |
Sutro Biopharma
May 19, 2025
Maintains: Underperform
Price Target: $1 → $0.8
Current: $0.92
Upside: -13.04%
Denali Therapeutics
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $13.42
Upside: +101.19%
Apellis Pharmaceuticals
May 9, 2025
Downgrades: Neutral
Price Target: $41 → $23
Current: $17.44
Upside: +31.88%
PTC Therapeutics
May 9, 2025
Upgrades: Buy
Price Target: $55 → $68
Current: $45.93
Upside: +48.05%
Rhythm Pharmaceuticals
Apr 10, 2025
Maintains: Buy
Price Target: $63 → $68
Current: $62.32
Upside: +9.11%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $302 → $325
Current: $289.96
Upside: +12.08%
Arvinas
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $6.51
Upside: +330.11%
Merus
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $55.14
Upside: +26.95%
4D Molecular Therapeutics
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $3.49
Upside: +1,046.13%
Neurocrine Biosciences
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $120.18
Upside: +48.94%
Dec 19, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $6.58
Upside: +234.35%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $11.47
Upside: +91.80%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.46
Upside: +105.48%
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $64.25
Upside: +40.08%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $6.22
Upside: +141.16%
Oct 9, 2024
Maintains: Underperform
Price Target: $11 → $6
Current: $6.53
Upside: -8.12%
Sep 23, 2024
Maintains: Buy
Price Target: $175 → $191
Current: $162.00
Upside: +17.90%
Sep 16, 2024
Maintains: Buy
Price Target: $125 → $150
Current: $98.68
Upside: +52.01%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $6.44
Upside: -68.94%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $587.61
Upside: +3.30%
Jun 21, 2024
Maintains: Buy
Price Target: $166 → $213
Current: $37.90
Upside: +462.01%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $35.66
Upside: +113.12%
May 10, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $21.98
Upside: +0.09%
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $3.96
Upside: +253.54%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $2.11
Upside: +373.93%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.16
Upside: +417.24%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $7.31
Upside: +105.34%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $15.99
Upside: -31.21%
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $10.59
Upside: -5.57%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $2.43
Upside: -17.70%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $0.88
Upside: +581.90%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $8.07
Upside: +85.87%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $37.49
Upside: +60.04%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.23
Upside: +1,200.81%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $9.49
Upside: +353.11%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $168.77
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $8.53
Upside: +3,419.06%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $0.70
Upside: +1,191.25%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $25.82
Upside: +85.90%